ESMO 2020: Sotorasib Shows Promise in Phase I Trial of Non-Small Cell Lung Cancer
This novel, first-in-class KRAS p.G12C inhibitor is being evaluated alone and in combination for other solid tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.